FDA says it is weighing PMTA framework changes as of 28 September 2026

The same page sets out no proposed text, no comment window and no timetable for any revision.

That leaves the current framework standing. The agency finalized the PMTA rule in 2021, and it describes the required content, format and review of applications. Manufacturers must also keep records showing their products are legally marketed.

What the FDA says about the substance of a PMTA

Any person may submit a PMTA for any new tobacco product seeking a marketing order, under section 910(b) of the Federal Food, Drug and Cosmetic Act, according to the FDA page. The application must supply scientific data showing the product is appropriate for the protection of public health.

The agency lists four considerations under section 910(c)(4), among others:

• Risks and benefits to the population as a whole, including users and nonusers;
• Whether current users of any tobacco product would be more or less likely to stop if the product were available;
• Whether people who do not use tobacco would be more or less likely to start if the product were available;
• The methods, facilities and controls used to manufacture, process and pack the product.

The finalized rule also covers amending or withdrawing an application, how the FDA communicates with applicants, and the agency’s disclosure procedures.

Four review stages, each with its own letter

Each stage ends in a defined output, and the rejection letters are the early signals a buyer can check.

An order comes with postmarket records duties

A marketing granted order does not end the paperwork. Holders must establish and maintain records and file reports the FDA requires under § 1114.41, and the agency may add reporting conditions in the order terms. The stated purpose is to help the agency decide whether grounds exist to withdraw or temporarily suspend the order.

A deficiency letter does not approve or reject a product. It states that more information is needed to complete scientific review and sets the number of days the applicant has to respond. An environmental information request letter follows a scientific decision to issue a marketing granted order, but blocks that order until the applicant supplies the environmental information.

What changes for buyers and for the supply side

A retailer checking status should read the letter type attached to a product, not the brand’s marketing, because only a marketing granted order authorises marketing under this framework. Products carrying an RTA, RTF or denial order sit in a different position from products still under review.

For exporters, distributors and Shenzhen-based manufacturers, the near-term compliance work stays as it was: assembling the scientific, manufacturing and environmental material the four considerations and the 2021 rule require, and keeping the records under § 1114.41 once an order is granted. VapeBrief’s analysis: the 28 September 2026 notice signals possible future change in the framework, so order timing and product-registration plans carry a planning risk the FDA page does not quantify. The agency has not published a proposal to price or schedule against.

The limits of what the page tells you

The FDA page does not describe what changes it is considering, whether any future rule would apply to pending applications, or when a decision might come. The 28 September 2026 notice is an expression of intent, not a proposed or final rule.

Manufacturers and importers should watch for a formal proposal or Federal Register notice that would supply the missing text. Until then, the 2021 final rule and the review stages described above remain the basis for any stock decision.

Questions readers ask

Is the PMTA framework changing now?

No. The FDA page says the agency intends to evaluate changes as of 28 September 2026, which is an expression of intent. The 2021 final PMTA rule described by the FDA remains the published framework.

Which letter shows a product may be marketed?

A marketing granted order. An acceptance letter, filing letter or deficiency letter reflects a review stage, and an RTA, RTF or marketing denial order does not authorise marketing.